

Stefano Taddei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4790325/publications.pdf>

Version: 2024-02-01

124
papers

7,167
citations

76326
40
h-index

58581
82
g-index

141
all docs

141
docs citations

141
times ranked

8688
citing authors

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. European Heart Journal, 2022, 43, 442-444.	2.2	0
2	The relationship between telomere length and putative markers of vascular ageing: A systematic review and meta-analysis. Mechanisms of Ageing and Development, 2022, 201, 111604.	4.6	9
3	Increased Collagen Turnover Is a Feature of Fibromuscular Dysplasia and Associated With Hypertrophic Radial Remodeling: A Pilot, Urine Proteomic Study. Hypertension, 2022, 79, 93-103.	2.7	4
4	Microvascular Inflammation and Cardiovascular Prevention: The Role of Microcirculation as Earlier Determinant of Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 41-48.	2.2	8
5	Arterial Hypertension and Cardiopulmonary Function: The Value of a Combined Cardiopulmonary and Echocardiography Stress Test. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 145.	2.2	1
6	Exercise-induced pulmonary hypertension in HFpEF and HFrEF: Different pathophysiologic mechanism behind similar functional impairment. Vascular Pharmacology, 2022, 144, 106978.	2.1	15
7	Ventricular-Arterial Coupling Derived From Proximal Aortic Stiffness and Aerobic Capacity Across the Heart Failure Spectrum. JACC: Cardiovascular Imaging, 2022, 15, 1545-1559.	5.3	16
8	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. European Heart Journal, 2021, 42, 2590-2604.	2.2	74
9	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovascular Research, 2021, 117, 29-42.	3.8	164
10	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI) clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	3.8	33
11	Cardiac Reserve and Exercise Capacity: Insights from Combined Cardiopulmonary and Exercise Echocardiography Stress Testing. Journal of the American Society of Echocardiography, 2021, 34, 38-50.	2.8	47
12	Pressure-Corrected Carotid Stiffness and Young's Modulus: Evaluation in an Outpatient Clinic Setting. American Journal of Hypertension, 2021, 34, 737-743.	2.0	13
13	Hypertension and COVID-19: Ongoing Controversies. Frontiers in Cardiovascular Medicine, 2021, 8, 639222.	2.4	38
14	Association between myocardial work and functional capacity in patients with arterial hypertension: an echocardiographic study. Blood Pressure, 2021, 30, 188-195.	1.5	14
15	Effects of Low-Carbohydrate versus Mediterranean Diets on Weight Loss, Glucose Metabolism, Insulin Kinetics and β -Cell Function in Morbidly Obese Individuals. Nutrients, 2021, 13, 1345.	4.1	24
16	Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction. ESC Heart Failure, 2021, 8, 2660-2669.	3.1	22
17	Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. Journal of Clinical Medicine, 2021, 10, 2495.	2.4	9
18	Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. European Heart Journal, 2021, 42, 2052-2059.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 1037-1046.	2.9	10
20	Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1858-1871.	7.1	86
21	Predicting the transition to and progression of heart failure with preserved ejection fraction: a weighted risk score using bio-humoral, cardiopulmonary, and echocardiographic stress testing. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1650-1661.	1.8	44
22	Donepezil improves vascular function in a mouse model of Alzheimer's disease. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00871.	2.4	4
23	An Integrated Management System for Noncommunicable Diseases Program Implementation in a Sub-Saharan Setting. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11619.	2.6	1
24	Microvascular Ageing Links Metabolic Disease to Age-Related Disorders: The Role of Oxidative Stress and Inflammation in Promoting Microvascular Dysfunction. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, S78-S87.	1.9	17
25	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. <i>Heart Failure Reviews</i> , 2020, 25, 31-42.	3.9	52
26	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.1	93
27	Scientific integrity: what a journal can and cannot do. <i>European Heart Journal</i> , 2020, 41, 4552-4555.	2.2	18
28	Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. <i>Obesity Research and Clinical Practice</i> , 2020, 14, 205-209.	1.8	89
29	Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 109-117.	2.2	16
30	Impact of Postprandial Hypoglycemia on Weight Loss After Bariatric Surgery. <i>Obesity Surgery</i> , 2020, 30, 2266-2273.	2.1	19
31	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. <i>Journal of Clinical Medicine</i> , 2020, 9, 2027.	2.4	12
32	Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling. <i>Obesity</i> , 2020, 28, 609-615.	3.0	17
33	Statin therapy in COVID-19 infection. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 258-259.	3.0	154
34	Letter to the Editor: Importance of metabolic health in the era of COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154247.	3.4	23
35	ACE-inhibitor/calcium antagonist combination: is this the first-choice therapy in arterial hypertension?. <i>Minerva Medica</i> , 2020, 110, 546-554.	0.9	2
36	The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4253-4263.	3.6	57

#	ARTICLE	IF	CITATIONS
37	Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 321-329.	2.2	17
38	Hemodynamic and autonomic effects of low-dose glyceryl trinitrate used to test endothelium-independent vasodilation of the brachial artery. Vascular Pharmacology, 2019, 120, 106576.	2.1	3
39	Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2019, 21, 2587-2598.	4.4	63
40	Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. European Heart Journal, 2019, 40, 2534-2547.	2.2	532
41	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. Cardiovascular Research, 2019, 116, 429-437.	3.8	20
42	Macrovasculature and Microvasculature at the Crossroads Between Type 2 Diabetes Mellitus and Hypertension. Hypertension, 2019, 73, 1138-1149.	2.7	111
43	The difficult relationship between uric acid and cardiovascular disease. European Heart Journal, 2019, 40, 3055-3057.	2.2	19
44	Microvascular Endothelial Dysfunction in Patients with Obesity. Current Hypertension Reports, 2019, 21, 32.	3.5	53
45	Drug-induced hypertension: Know the problem to know how to deal with it. Vascular Pharmacology, 2019, 115, 84-88.	2.1	14
46	Microvascular Endothelial Dysfunction in Human Obesity: Role of TNF- α . Journal of Clinical Endocrinology and Metabolism, 2019, 104, 341-348.	3.6	54
47	Renal Resistive Index Predicts Post-Bariatric Surgery Renal Outcome in Nondiabetic Individuals with Severe Obesity. Obesity, 2019, 27, 68-74.	3.0	10
48	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. European Heart Journal, 2019, 40, 383-391.	2.2	45
49	Vascular Function Is Improved After an Environmental Enrichment Program. Hypertension, 2018, 71, 1218-1225.	2.7	18
50	Statin guidelines: Friend or foes?. European Journal of Preventive Cardiology, 2018, 25, 867-869.	1.8	0
51	Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes. Current Medical Research and Opinion, 2018, 34, 1557-1570.	1.9	2
52	Essential Hypertension and Functional Microvascular Ageing. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 35-40.	2.2	31
53	Ageing Modulates the Influence of Arginase on Endothelial Dysfunction in Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2474-2483.	2.4	41
54	Asleep blood pressure: a target for cardiovascular event reduction?. European Heart Journal, 2018, 39, 4172-4174.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Need for fixed combination therapy in type-2 diabetes: Findings from the SMART study. European Journal of Preventive Cardiology, 2018, 25, 1520-1522.	1.8	0
56	Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome. Vascular Pharmacology, 2017, 92, 16-21.	2.1	11
57	The year in cardiology 2016: prevention. European Heart Journal, 2017, 38, ehw637.	2.2	1
58	Understanding the role of genetics in hypertension. European Heart Journal, 2017, 38, 2309-2312.	2.2	41
59	Olfactory evaluation in Mild Cognitive Impairment: correlation with neurocognitive performance and endothelial function. European Journal of Neuroscience, 2017, 45, 1279-1288.	2.6	20
60	Carotid and aortic stiffness in essential hypertension and their relation with target organ damage. Journal of Hypertension, 2017, 35, 310-318.	0.5	40
61	Arterial-ventricular coupling and parameters of vascular stiffness in hypertensive patients: Role of gender. JRSM Cardiovascular Disease, 2017, 6, 204800401769227.	0.7	9
62	Different Impact of Essential Hypertension on Structural and Functional Age-Related Vascular Changes. Hypertension, 2017, 69, 71-78.	2.7	63
63	Impact of seasonality and air pollutants on carotid-femoral pulse wave velocity and wave reflection in hypertensive patients. PLoS ONE, 2017, 12, e0172550.	2.5	11
64	Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovascular Diabetology, 2017, 16, 138.	6.8	274
65	Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. Journal of Neurogastroenterology and Motility, 2017, 23, 428-434.	2.4	24
66	Abstract P509: Identification of Radial Vascular Wall Abnormalities by Very-high Frequency Ultrasound in Patients With Fibromuscular Dysplasia: The Fuchsia Study. Hypertension, 2017, 70, .	2.7	6
67	Environmental Factors and Hypertension. Current Pharmaceutical Design, 2017, 23, 3239-3246.	1.9	27
68	Renal denervation for resistant hypertension: no. Internal and Emergency Medicine, 2016, 11, 495-498.	2.0	1
69	Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 347-353.	2.2	2
70	Renal denervation: a blunt weapon against isolated systolic hypertension?. European Heart Journal, 2016, 38, ehw460.	2.2	5
71	Impact of apocynin on vascular disease in hypertension. Vascular Pharmacology, 2016, 87, 1-5.	2.1	28
72	Endothelial dysfunction in hypertension. Journal of Hypertension, 2016, 34, 1492-1493.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity. American Journal of Cardiovascular Drugs, 2016, 16, 309-321.	2.2	66
74	Gender differences in the relationships between psychosocial factors and hypertension. Maturitas, 2016, 93, 58-64.	2.4	18
75	Relationship between insomnia symptoms, perceived stress and coping strategies in subjects with arterial hypertension: psychological factors may play a modulating role. Sleep Medicine, 2016, 19, 108-115.	1.6	30
76	Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 489-495.	0.7	12
77	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. Hypertension, 2016, 67, e3-4.	2.7	1
78	New-onset diabetes in hypertensive patients and mortality: timing is everything. European Heart Journal, 2016, 37, 975-977.	2.2	7
79	Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase. Vascular Pharmacology, 2016, 76, 62-71.	2.1	25
80	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 277.	3.5	55
81	RAS inhibitors™ dose-dependent efficacy: myth or reality?. Current Medical Research and Opinion, 2015, 31, 1245-1256.	1.9	13
82	Renal denervation: back to reality, finally!. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 57-57.	3.0	0
83	Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. European Heart Journal, 2015, 36, 784-794.	2.2	127
84	Combination Therapy in Hypertension: What Are the Best Options According to Clinical Pharmacology Principles and Controlled Clinical Trial Evidence?. American Journal of Cardiovascular Drugs, 2015, 15, 185-194.	2.2	33
85	Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. European Heart Journal, 2015, 36, ehv365.	2.2	30
86	Evaluation of microvascular structure in humans. Journal of Hypertension, 2014, 32, 2120-2129.	0.5	53
87	Impact of inflammation on vascular disease in hypertension. Maturitas, 2014, 78, 179-183.	2.4	95
88	Renal denervation and regression of left ventricular hypertrophy. European Heart Journal, 2014, 35, 2205-2207.	2.2	5
89	Prognostic value of flow mediated dilation in patients with systemic lupus erythematosus: A pilot prospective cohort study. Atherosclerosis, 2014, 236, 381-384.	0.8	10
90	Fixed-Dose Combination Therapy in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 55-57.	2.2	12

#	ARTICLE	IF	CITATIONS
91	The Correct Administration of Antihypertensive Drugs According to the Principles of Clinical Pharmacology. American Journal of Cardiovascular Drugs, 2011, 11, 13-20.	2.2	23
92	Vascular Generation of Tumor Necrosis Factor- α Reduces Nitric Oxide Availability in Small Arteries From Visceral Fat of Obese Patients. Journal of the American College of Cardiology, 2011, 58, 238-247.	2.8	98
93	Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Failure Reviews, 2011, 16, 615-620.	3.9	74
94	Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander?. European Heart Journal, 2010, 31, 1168-1171.	2.2	26
95	Secondary Hypertension and Essential Thrombocythaemia. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 49-52.	2.2	0
96	Fixed Dose Combination of Perindopril and Indapamide Improves Peripheral Vascular Function in Essential Hypertensive Patients. American Journal of Hypertension, 2009, 22, 506-512.	2.0	31
97	Response to Letter Regarding Article, "Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients" Circulation, 2009, 120, .	1.6	0
98	Synergistic Effects of Calcium Antagonists and Statins on Endothelial Function. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 123-131.	2.2	0
99	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 61-72.	2.2	0
100	Identification of a Cytochrome P450 2C9-Derived Endothelium-Derived Hyperpolarizing Factor in Essential Hypertensive Patients. Journal of the American College of Cardiology, 2006, 48, 508-515.	2.8	105
101	Endothelium, aging, and hypertension. Current Hypertension Reports, 2006, 8, 84-89.	3.5	108
102	Which endothelium-derived factors are really important in humans?. Biological Chemistry, 2006, 387, 151-7.	2.5	2
103	Low-Grade Systemic Inflammation Causes Endothelial Dysfunction in Patients with Hashimoto's Thyroiditis. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 5076-5082.	3.6	156
104	Evolving the concept of regulation of vascular tone in humans. British Journal of Pharmacology, 2005, 146, 165-166.	5.4	2
105	Reconsidering the Treatment of Patients with Coronary Artery Disease. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 67-72.	2.2	0
106	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	2.2	0
107	Endothelial Dysfunction, Vascular Damage and Clinical Events. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 15-27.	2.2	3
108	Current Treatment of Patients with Hypertension. Drugs, 2003, 63, 1435-1444.	10.9	7

#	ARTICLE	IF	CITATIONS
109	Is Endothelial Dysfunction a Measurable Endpoint in Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 19-25.	2.2	0
110	Impaired Endothelium-Dependent Vasodilatation in Subclinical Hypothyroidism: Beneficial Effect of Levothyroxine Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3731-3737.	3.6	379
111	Different Effect of Antihypertensive Drugs on Conduit Artery Endothelial Function. Hypertension, 2003, 41, 1281-1286.	2.7	330
112	Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension. Hypertension, 2003, 41, 950-955.	2.7	49
113	Combination of lisinopril and nifedipine GITS Increases Blood Pressure Control Compared with Single Drugs in Essential Hypertensive Patients. Journal of Cardiovascular Pharmacology, 2003, 41, 579-585.	1.9	13
114	Effects of Antihypertensive Drugs on Endothelial Dysfunction. Drugs, 2002, 62, 265-284.	10.9	150
115	Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Failure Reviews, 2001, 6, 277-285.	3.9	38
116	Age-Related Reduction of NO Availability and Oxidative Stress in Humans. Hypertension, 2001, 38, 274-279.	2.7	595
117	Restoration of Nitric Oxide Availability After Calcium Antagonist Treatment in Essential Hypertension. Hypertension, 2001, 37, 943-948.	2.7	145
118	Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Current Hypertension Reports, 2000, 2, 64-70.	3.5	62
119	Effect of the Angiotensin II Type 1 Receptor Blocker Candesartan on Endothelial Function in Patients With Essential Hypertension. Hypertension, 2000, 35, 501-506.	2.7	176
120	Physical Activity Prevents Age-Related Impairment in Nitric Oxide Availability in Elderly Athletes. Circulation, 2000, 101, 2896-2901.	1.6	402
121	Vasodilation to Bradykinin Is Mediated by an Ouabain-Sensitive Pathway as a Compensatory Mechanism for Impaired Nitric Oxide Availability in Essential Hypertensive Patients. Circulation, 1999, 100, 1400-1405.	1.6	123
122	Aging and Endothelial Function in Normotensive Subjects and Patients With Essential Hypertension. Circulation, 1995, 91, 1981-1987.	1.6	577
123	Hemodynamic and Humoral Effects of Low-Dose Aspirin in Treated and Untreated Essential Hypertensive Patients. Blood Pressure, 1994, 3, 236-241.	1.5	20
124	Relationship between Insulin Release, Antinatriuresis and Hypokalaemia after Glucose Ingestion in Normal and Hypertensive Man. Clinical Science, 1993, 85, 327-335.	4.3	63